Ocular Therapeutix Inc (NASDAQ:OCUL) currently has a daily average trading volume of 1.22M but it saw 2463223 shares traded in last market. With a market cap of 1.79B USD, the company’s current market price of $11.47 came rising about 12.12 while comparing to the previous closing price of $10.23. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.31 and as low as $2.00. In the recent trading on the day, stock has struck highest price mark of $10.3544 while lowest mark touched by it was $11.58.
Taking a look at 20-day trading activity of Ocular Therapeutix Inc (OCUL) gives us an average price of $9.34, while its current price level is 1.41% below from 52-week high level whereas it is 474.94% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $8.89 while that of 200 days or SMA-200 reads an average of $7.33. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.01% during that period while stretching the period over a month that decreases to 6.04%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 75.24 which implies that the stock is in overbought territory.
TD Cowen upgraded its recommendation for the stock as a “Buy” from “Hold” on June 20, 2024 while assigning a price target range of $7-$11. Piper Sandler issued its recommendations for the stock as it resumed the price target for the stock is $15.
Over the week, OCUL’s stock price is moving 23.33% up while it is 30.94% when we observe its performance for the past one month. Year-to-date it is 157.17% up and over the past year, the stock is showing an upside performance of 356.97%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.01 beat the consensus estimate of -0.29 for the same. The company is expected to be releasing its next quarterly report in November, for which analysts forecasted an EPS of -0.24 while estimate for next year EPS is -1.17. In next quarter, company is expected to be making quarterly sales of $17.75M as analysts are expecting the sales for current fiscal year at $66.18M and seeing the company making $74.95M in sales next year. Moreover, analysts are in estimates of $17.13M for current-quarter revenue.
Currently, Ocular Therapeutix Inc’s total number of outstanding shares is 155.92M. Company’s return on investment (ROI) stands at -30.68% and return on equity (ROE) at -72.67%. Stock’s beta reads 1.28. Stock has a price to book (P/B) ratio of 4.73 while price to sale or P/S ratio amounts to 29.27. Its return on asset (ROA) is -43.26% on average.
